

Supplementary Table 1. Univariable Cox proportional hazards regression for overall survival and progression-free survival.

Variable	Overall survival (N = 58)		Progression-free survival (N = 60)	
	HR (95% CI)	P value	HR (95% CI)	P value
<i>BCLC stage</i>				
Stage A	1.54 (0.50–4.76)	0.454	1.94 (0.73–5.14)	0.185
Stage B	2.54 (0.88–7.31)	0.084	1.93 (0.77–4.85)	0.161
Stage C	3.87 (1.27–11.80)	0.017	3.51 (1.26–9.78)	0.016
Overall LR test		0.066		0.109
<i>ALBI</i>				
Grade 2	1.17 (0.54–2.51)	0.693	1.12 (0.59–2.13)	0.727
Grade 3	Inestimable ^a	—	0.47 (0.06–3.57)	0.462
Overall LR test		0.219		0.592
Child-Pugh score (per unit)	1.12 (0.78–1.61)	0.550	1.06 (0.78–1.44)	0.707
Tumour size (per 10 mm)	1.34 (1.06–1.70)	0.016	1.14 (0.93–1.40)	0.216
BED ₁₀ (per 10 Gy)	0.86 (0.69–1.07)	0.190	1.01 (0.85–1.20)	0.874
Vascular invasion (yes vs no)	2.68 (1.00–7.14)	0.049	2.96 (1.23–7.11)	0.015

^aALBI grade 3 OS hazard ratio was inestimable due to complete separation (n = 2, no events in this subgroup).

HR, hazard ratio; CI, confidence interval; LR, likelihood ratio; BCLC, Barcelona Clinic Liver Cancer; ALBI, albumin-bilirubin; BED₁₀, biologically effective dose (α/β = 10 Gy); SBRT, stereotactic body radiotherapy